Ipratropium solution administered either alone or with a beta-adrenergic stimulant solution is indicated as a bronchodilator for the maintenance treatment of bronchospasm associated with, or for the therapy of acute exacerbations of chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Ipratropium solution, when used in conjunction with a beta-adrenergic stimulant solution such as fenoterol or salbutamol, is indicated for acute asthmatic attacks. It is to be administered by compressed air or oxygen-driven nebulizers.. . Contraindications: Known hypersensitivity to ipratropium, to any of the product's ingredients or to atropinics.